Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | CLPP | Q16740 | 16/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13329264 | 0.92 | CLPP (0.52) | CYP1A2GAACYP2C9ADORA2ACLPP | |
| SCHEMBL13329275 | 0.90 | MEN1 (0.49) | CYP1A2GAACYP2C9ADORA2ACLPP | |
| SCHEMBL13329143 | 0.89 | CLPP (0.52) | CYP1A2GAACYP2C9ADORA2ACLPP | |
| SCHEMBL13329228 | 0.89 | CLPP (0.51) | CYP1A2GAACYP2C9ADORA2ACLPP | |
| SCHEMBL13329281 | 0.89 | CLPP (0.39) | CYP1A2GAACYP2C9ADORA2ACLPP | |
| SCHEMBL13329155 | 0.89 | CYP1A2 (0.43) | CYP1A2GAACYP2C9ADORA2ACLPP | |
| SCHEMBL13329052 | 0.89 | CLPP (0.50) | CYP1A2GAACYP2C9ADORA2ACLPP | |
| SCHEMBL13328799 | 0.88 | CYP1A2 (0.53) | CYP1A2GAACYP2C9ADORA2ACLPP | |
| SCHEMBL13329031 | 0.87 | CLPP (0.54) | CYP1A2GAACYP2C9ADORA2ACLPP | |
| SCHEMBL13329072 | 0.87 | CLPP (0.54) | CYP1A2GAACYP2C9ADORA2ACLPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318751-B2 | Pyrimidinone derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318751-B2 | Pyrimidinone derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GPR180, GPR17 | CYP1A2 1604/4885GAA 913/4885CYP2C9 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.